RxDoctor Payments Data

Rakhi Barkowski, MD

Internal Medicine · Amherst, NYNPI 1043458367

Payments from drug & device makers

$848in general payments, 2019–2025

Across 12 payments — averaging $70.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inari Medical, Inc.$199
  • Acadia Pharmaceuticals Inc$134
  • Pfizer$134
  • Otsuka America Pharmaceutical, Inc.$125
  • AstraZeneca$117
  • Johnson & Johnson$61
  • plus $77 from 3 others

What the payments were for

  • Food & beverage$848100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$848 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$120,274
Medicare patients
215
Services billed
1,053

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban335$98,133
Austedo XrDeutetrabenazine20$55,761
NuplazidPimavanserin Tartrate16$39,026
JardianceEmpagliflozin101$30,826
XifaxanRifaximin20$27,622
NuedextaDextromethorphan Hbr/Quinidine32$25,321
Trelegy ElliptaFluticasone/Umeclidin/Vilanter25$17,377
XareltoRivaroxaban52$16,647
JanuviaSitagliptin Phosphate50$14,659
EntrestoSacubitril/Valsartan42$14,474
TrulicityDulaglutide12$12,866
SantylCollagenase Clostridium Hist.17$8,962
LantusInsulin Glargine,hum.Rec.Anlog70$5,115
Incruse ElliptaUmeclidinium Bromide12$4,550
Gabapentin144$4,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$134$98,133335 claims
Acadia Pharmaceuticals IncNuplazid$134$39,02616 claims
Johnson & JohnsonXarelto$61$16,64752 claims
NovartisEntresto$26$14,47442 claims
AstraZenecaBrilinta, Symbicort$117$6,66931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Amherst

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →